"Varenicline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.
| Descriptor ID |
D000068580
|
| MeSH Number(s) |
D03.633.100.079.900 D03.633.100.857.942
|
| Concept/Terms |
Varenicline- Varenicline
- 6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine
|
Below are MeSH descriptors whose meaning is more general than "Varenicline".
Below are MeSH descriptors whose meaning is more specific than "Varenicline".
This graph shows the total number of publications written about "Varenicline" by people in this website by year, and whether "Varenicline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 4 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Varenicline" by people in Profiles.
-
Martin RA, Rohsenow DJ, Tidey JW. Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. J Subst Abuse Treat. 2019 09; 104:22-27.
-
Versace F, Stevens EM, Robinson JD, Cui Y, Deweese MM, Engelmann JM, Green CE, Karam-Hage M, Lam CY, Minnix JA, Wetter DW, Cinciripini PM. Brain Responses to Cigarette-Related and Emotional Images in Smokers During Smoking Cessation: No Effect of Varenicline or Bupropion on the Late Positive Potential. Nicotine Tob Res. 2019 01 04; 21(2):234-240.
-
Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, Monti PM. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction. 2017 Oct; 112(10):1808-1820.
-
Murphy CM, MacKillop J, Martin RA, Tidey JW, Colby SM, Rohsenow DJ. Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders. Psychopharmacology (Berl). 2017 Aug; 234(16):2443-2452.
-
Slater CA, Jackson A, Muldoon PP, Dawson A, O'Brien M, Soll LG, Abdullah R, Carroll FI, Tapper AR, Miles MF, Banks ML, Bettinger JC, Damaj IM. Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse. Alcohol Clin Exp Res. 2016 Jan; 40(1):62-72.
-
Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011; 6(11):e27016.
-
Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011 Sep 06; 183(12):1359-66.
-
King J, Huang W, Chen W, Heffernan M, Shields J, Rane P, Bircher R, DiFranza JR. A comparison of brain and behavioral effects of varenicline and nicotine in rats. Behav Brain Res. 2011 Sep 30; 223(1):42-7.
-
Hendrickson LM, Gardner P, Tapper AR. Nicotinic acetylcholine receptors containing the a4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption. Channels (Austin). 2011 Mar-Apr; 5(2):124-7.
-
Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci. 2010 Jul 28; 30(30):10169-76.